Skip to main content
Top
Published in: Pediatric Nephrology 6/2009

01-06-2009 | Review

Severe hypertension in children and adolescents: pathophysiology and treatment

Authors: Joseph T. Flynn, Kjell Tullus

Published in: Pediatric Nephrology | Issue 6/2009

Login to get access

Abstract

Severe, symptomatic hypertension occurs uncommonly in children, usually only in those with underlying congenital or acquired renal disease. If such hypertension has been long-standing, then rapid blood pressure reduction may be risky due to altered cerebral hemodynamics. While many drugs are available for the treatment of severe hypertension in adults, few have been studied in children. Despite the lack of scientific studies, some agents, particularly continuous intravenous infusions of nicardipine and labetalol, are preferred in many centers. These agents generally provide the ability to control the magnitude and rapidity of blood pressure reduction and should—in conjunction with careful patient monitoring—allow the safe reduction of blood pressure and the avoidance of complications. This review provides a summary of the underlying causes and pathophysiology of acute severe hypertension in childhood as well as a detailed discussion of drug treatment and the optimal clinical approach to managing children and adolescents with acute severe hypertension.
Literature
1.
go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2005) The Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Institute of Health publication 05:5267. Bethesda, MD, National Heart, Lung, and Blood Institute National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2005) The Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Institute of Health publication 05:5267. Bethesda, MD, National Heart, Lung, and Blood Institute
2.
3.
go back to reference Haas CE, LeBlanc JM (2004) Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm 61:1661–1673CrossRefPubMed Haas CE, LeBlanc JM (2004) Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm 61:1661–1673CrossRefPubMed
4.
go back to reference Flynn JT (2005) Hypertension in childhood and adolescence. In: Kaplan NM (ed) Kaplan’s clinical hypertension, 9th edn. Lippincott-Williams and Wilkins, Philadelphia, pp 465–488 Flynn JT (2005) Hypertension in childhood and adolescence. In: Kaplan NM (ed) Kaplan’s clinical hypertension, 9th edn. Lippincott-Williams and Wilkins, Philadelphia, pp 465–488
6.
go back to reference Flynn JT, Mottes TA, Brophy PB, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43CrossRefPubMed Flynn JT, Mottes TA, Brophy PB, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43CrossRefPubMed
7.
go back to reference Bender SR, Fong MW, Heitz S, Bisognano JD (2006) Characteristics and management of patients presenting to the emergency department with hypertensive urgency. J Clin Hypertens 8:12–18CrossRef Bender SR, Fong MW, Heitz S, Bisognano JD (2006) Characteristics and management of patients presenting to the emergency department with hypertensive urgency. J Clin Hypertens 8:12–18CrossRef
8.
go back to reference Rose JC, Mayer SA (2004) Optimizing blood pressure in neurological emergencies. Neurocrit Care 1:287–299CrossRefPubMed Rose JC, Mayer SA (2004) Optimizing blood pressure in neurological emergencies. Neurocrit Care 1:287–299CrossRefPubMed
9.
go back to reference Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, Chan M, Barkovics M, McLaren CA, Shah V, Dillon MJ, Tullus K (2006) Angioplasty for renovascular hypertension in children: 20-year experience. Pediatrics 118:268–275CrossRefPubMed Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, Chan M, Barkovics M, McLaren CA, Shah V, Dillon MJ, Tullus K (2006) Angioplasty for renovascular hypertension in children: 20-year experience. Pediatrics 118:268–275CrossRefPubMed
11.
go back to reference Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL (1992) Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159:379–383CrossRefPubMed Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL (1992) Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159:379–383CrossRefPubMed
12.
go back to reference Flynn JT, Woroniecki RP (2003) Pathophysiology of hypertension. In: Avner E, Harmon W, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1153–1178 Flynn JT, Woroniecki RP (2003) Pathophysiology of hypertension. In: Avner E, Harmon W, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1153–1178
13.
go back to reference Funakoshi Y, Ichiki T, Ito K, Takeshita A (1999) Induction of interleukin-6 expression by angiotensin II in rat vascular smooth vascular cells. Hypertension 34:118–125CrossRefPubMed Funakoshi Y, Ichiki T, Ito K, Takeshita A (1999) Induction of interleukin-6 expression by angiotensin II in rat vascular smooth vascular cells. Hypertension 34:118–125CrossRefPubMed
14.
go back to reference Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344:541–544CrossRefPubMed Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344:541–544CrossRefPubMed
15.
go back to reference Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR (1998) Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 16:635–643CrossRefPubMed Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR (1998) Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 16:635–643CrossRefPubMed
16.
go back to reference Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI (1981) Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med 304:1067–1070CrossRefPubMed Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI (1981) Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med 304:1067–1070CrossRefPubMed
17.
go back to reference Brouwers FM, Eisenhofer G, Lenders JW, Pacak K (2006) Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin North Am 35:699–724CrossRefPubMed Brouwers FM, Eisenhofer G, Lenders JW, Pacak K (2006) Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin North Am 35:699–724CrossRefPubMed
18.
go back to reference Rauth W, Hund E, Sohl G, Rascher W, Mehls O, Scharer K (1983) Vasoactive hormones in children with chronic renal failure. Kidney Int Suppl 15:S27–S33 Rauth W, Hund E, Sohl G, Rascher W, Mehls O, Scharer K (1983) Vasoactive hormones in children with chronic renal failure. Kidney Int Suppl 15:S27–S33
19.
go back to reference Faber JE, Brody MA (1985) Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 57:676–688CrossRefPubMed Faber JE, Brody MA (1985) Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 57:676–688CrossRefPubMed
20.
go back to reference Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ (1995) Endothelin in the kidney in malignant phase hypertension. Hypertension 26:925–931CrossRefPubMed Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ (1995) Endothelin in the kidney in malignant phase hypertension. Hypertension 26:925–931CrossRefPubMed
21.
go back to reference Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ (1998) Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 274:F642–F649PubMed Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ (1998) Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 274:F642–F649PubMed
22.
23.
go back to reference Patel H, Mitsnefes M (2005) Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 17:210–214CrossRefPubMed Patel H, Mitsnefes M (2005) Advances in the pathogenesis and management of hypertensive crisis. Curr Opin Pediatr 17:210–214CrossRefPubMed
24.
go back to reference Muller DN, Dechend R, Mervaala EMA, Park J-K, Schmidt F, Fiebler A, Theuer J, Ganten D, Haller H, Luft FC (2000) NF-κB inhibition ameliorates angotensin II induce inflammatory damage in rats. Hypertension 35:193–201CrossRefPubMed Muller DN, Dechend R, Mervaala EMA, Park J-K, Schmidt F, Fiebler A, Theuer J, Ganten D, Haller H, Luft FC (2000) NF-κB inhibition ameliorates angotensin II induce inflammatory damage in rats. Hypertension 35:193–201CrossRefPubMed
25.
go back to reference Lip GYH, Edmunds E, Hee FL, Blann AD, Beevers DG (2001) A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 14:627–631CrossRefPubMed Lip GYH, Edmunds E, Hee FL, Blann AD, Beevers DG (2001) A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 14:627–631CrossRefPubMed
27.
go back to reference Grossman E, Messerli FH (2008) Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 10:556–566CrossRef Grossman E, Messerli FH (2008) Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 10:556–566CrossRef
29.
go back to reference Treluyer JM, Hubert P, Jouvet P, Couderc S, Cloup M (1993) Intravenous nicardipine in hypertensive children. Eur J Pediatr 152:712–714CrossRefPubMed Treluyer JM, Hubert P, Jouvet P, Couderc S, Cloup M (1993) Intravenous nicardipine in hypertensive children. Eur J Pediatr 152:712–714CrossRefPubMed
30.
go back to reference Michael J, Groshong T, Tobias JD (1998) Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 12:40–42CrossRefPubMed Michael J, Groshong T, Tobias JD (1998) Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 12:40–42CrossRefPubMed
31.
go back to reference Tenney F, Sakarcan A (2000) Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 35:E20CrossRefPubMed Tenney F, Sakarcan A (2000) Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 35:E20CrossRefPubMed
32.
go back to reference Nakagawa TA, Sartori SC, Morris A, Schneider DS (2004) Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 25:26–30CrossRefPubMed Nakagawa TA, Sartori SC, Morris A, Schneider DS (2004) Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 25:26–30CrossRefPubMed
33.
go back to reference Flynn JT (2003) Successes and shortcomings of the FDA Modernization Act. Am J Hypertens 16:889–891CrossRefPubMed Flynn JT (2003) Successes and shortcomings of the FDA Modernization Act. Am J Hypertens 16:889–891CrossRefPubMed
34.
go back to reference Dunne J (2007) The European Regulation on medicines for paediatric use. Paediatr Respir Rev 8:177–183CrossRefPubMed Dunne J (2007) The European Regulation on medicines for paediatric use. Paediatr Respir Rev 8:177–183CrossRefPubMed
36.
go back to reference Rocco TP, Fang JC (2006) Pharmacotherapy of congestive heart failure. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 869–898 Rocco TP, Fang JC (2006) Pharmacotherapy of congestive heart failure. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 869–898
37.
go back to reference Goa KL, Benfield P, Sorkin EM (1989) Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 37:583–627CrossRefPubMed Goa KL, Benfield P, Sorkin EM (1989) Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 37:583–627CrossRefPubMed
38.
go back to reference Bunchman TE, Lynch RE, Wood EG (1992) Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 120:140–144CrossRefPubMed Bunchman TE, Lynch RE, Wood EG (1992) Intravenously administered labetalol for treatment of hypertension in children. J Pediatr 120:140–144CrossRefPubMed
39.
go back to reference Flynn JT, Pasko DA (2000) Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15:302–316CrossRefPubMed Flynn JT, Pasko DA (2000) Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15:302–316CrossRefPubMed
40.
go back to reference Wallin JD, Bienvenu GS, Cook E, Laddu A, Turlapaty P, Clifton GG (1990) Nicardipine in severe hypertension: oral therapy following intravenous treatment. Int J Clin Pharmacol Ther Toxicol 28:14–19PubMed Wallin JD, Bienvenu GS, Cook E, Laddu A, Turlapaty P, Clifton GG (1990) Nicardipine in severe hypertension: oral therapy following intravenous treatment. Int J Clin Pharmacol Ther Toxicol 28:14–19PubMed
41.
go back to reference Hoffman BB (2006) Therapy of hypertension. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 845–868 Hoffman BB (2006) Therapy of hypertension. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 845–868
42.
go back to reference Alexander KS, Pudipeddi M, Parker GA (1993) Stability of hydralazine hydrochloride syrup compounded from tablets. Am J Hosp Pharm 50:683–686PubMed Alexander KS, Pudipeddi M, Parker GA (1993) Stability of hydralazine hydrochloride syrup compounded from tablets. Am J Hosp Pharm 50:683–686PubMed
43.
go back to reference Kirsten R, Nelson K, Kirsten D, Heintz B (1998) Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34:457–482CrossRefPubMed Kirsten R, Nelson K, Kirsten D, Heintz B (1998) Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 34:457–482CrossRefPubMed
44.
go back to reference McCrory WW, Kohaut EC, Lewy JE, Lieberman E, Travis LB (1979) Safety of intravenous diazoxide in children with severe hypertension. Clin Pediatr 18:661–667, 671CrossRef McCrory WW, Kohaut EC, Lewy JE, Lieberman E, Travis LB (1979) Safety of intravenous diazoxide in children with severe hypertension. Clin Pediatr 18:661–667, 671CrossRef
45.
go back to reference Grossman E, Ironi AN, Messerli FH (1998) Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 19:99–122CrossRefPubMed Grossman E, Ironi AN, Messerli FH (1998) Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 19:99–122CrossRefPubMed
46.
go back to reference Adamson PC, Rhodes LA, Saul JP, Dick M 2nd, Epstein MR, Moate P, Boston R, Schreiner MS (2006) The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 27:420–427CrossRefPubMed Adamson PC, Rhodes LA, Saul JP, Dick M 2nd, Epstein MR, Moate P, Boston R, Schreiner MS (2006) The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 27:420–427CrossRefPubMed
47.
go back to reference Wells TG, Bunchman TE, Kearns GL (1990) Treatment of neonatal hypertension with enalaprilat. J Pediatr 117:664–667CrossRefPubMed Wells TG, Bunchman TE, Kearns GL (1990) Treatment of neonatal hypertension with enalaprilat. J Pediatr 117:664–667CrossRefPubMed
48.
go back to reference Sica DA (2007) Centrally acting antihypertensive agents: An update. J Clin Hypertens (Greenwich) 9:399–405CrossRef Sica DA (2007) Centrally acting antihypertensive agents: An update. J Clin Hypertens (Greenwich) 9:399–405CrossRef
49.
go back to reference Falkner B, Onesti G, Lowenthal DT, Affrime MB (1983) The use of clonidine monotherapy in adolescent hypertension. Chest 83(Suppl 2):425–427CrossRefPubMed Falkner B, Onesti G, Lowenthal DT, Affrime MB (1983) The use of clonidine monotherapy in adolescent hypertension. Chest 83(Suppl 2):425–427CrossRefPubMed
50.
go back to reference MacDonald JL, Johnson CE, Jacobson P (1994) Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 51:2409–2411PubMed MacDonald JL, Johnson CE, Jacobson P (1994) Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 51:2409–2411PubMed
51.
go back to reference Strauser LM, Groshong T, Tobias JD (2000) Initial experience with isradipine for the treatment of hypertension in children. South Med J 93:287–293CrossRefPubMed Strauser LM, Groshong T, Tobias JD (2000) Initial experience with isradipine for the treatment of hypertension in children. South Med J 93:287–293CrossRefPubMed
52.
go back to reference Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 17:748–753CrossRefPubMed Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 17:748–753CrossRefPubMed
53.
go back to reference Saragoça MA, Portela JE, Plavnik F, Ventura RP, Lotaif L, Ramos OL (1992) Isradipine in the treatment of hypertensive crisis in ambulatory patients. J Cardiovasc Pharmacol 19(Suppl 3):S76–S78PubMed Saragoça MA, Portela JE, Plavnik F, Ventura RP, Lotaif L, Ramos OL (1992) Isradipine in the treatment of hypertensive crisis in ambulatory patients. J Cardiovasc Pharmacol 19(Suppl 3):S76–S78PubMed
54.
go back to reference Pennisi AJ, Takahashi M, Bernstein BH, Singsen BH, Uittenbogaart C, Ettenger RB, Malekzadeh MH, Hanson V, Fine RN (1977) Minoxidil therapy in children with severe hypertension. J Pediatr 90:813–819CrossRefPubMed Pennisi AJ, Takahashi M, Bernstein BH, Singsen BH, Uittenbogaart C, Ettenger RB, Malekzadeh MH, Hanson V, Fine RN (1977) Minoxidil therapy in children with severe hypertension. J Pediatr 90:813–819CrossRefPubMed
55.
go back to reference Strife CF, Quinlan M, Waldo FB, Fryer CJ, Jackson EC, Welch TR, McEnery PT, West CD (1986) Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 78:861–865PubMed Strife CF, Quinlan M, Waldo FB, Fryer CJ, Jackson EC, Welch TR, McEnery PT, West CD (1986) Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 78:861–865PubMed
56.
go back to reference Murphy MB, Murray C, Shorten GD (2001) Fenoldopam – a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548–1557CrossRefPubMed Murphy MB, Murray C, Shorten GD (2001) Fenoldopam – a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345:1548–1557CrossRefPubMed
57.
go back to reference Nordlander M, Sjöquist P-O, Ericsson H, Rydén L (2004) Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 22:227–250CrossRefPubMed Nordlander M, Sjöquist P-O, Ericsson H, Rydén L (2004) Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 22:227–250CrossRefPubMed
58.
go back to reference Powroznyk AVV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgård Å, Latimer RD, Nordlander M, Feneck RO (2003) Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 20:697–703CrossRefPubMed Powroznyk AVV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgård Å, Latimer RD, Nordlander M, Feneck RO (2003) Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 20:697–703CrossRefPubMed
59.
go back to reference Dooley M, Goa KL (1998) Urapidil. A reappraisal of its use in the management of hypertension. Drugs 56:929–955CrossRefPubMed Dooley M, Goa KL (1998) Urapidil. A reappraisal of its use in the management of hypertension. Drugs 56:929–955CrossRefPubMed
60.
go back to reference Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM (2006) Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens 20:707–709CrossRefPubMed Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM (2006) Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens 20:707–709CrossRefPubMed
Metadata
Title
Severe hypertension in children and adolescents: pathophysiology and treatment
Authors
Joseph T. Flynn
Kjell Tullus
Publication date
01-06-2009
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 6/2009
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-008-1000-1

Other articles of this Issue 6/2009

Pediatric Nephrology 6/2009 Go to the issue